Lung cancer is a malignant lung carcinoma that is characterized by abnormal cell growth in lung tissue. As the tumor grows in size, it decreases the lungs’ ability to provide oxygen to bloodstream. The primary lung carcinomas originate from epithelial cells and classified as non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Major symptoms of lung cancer include coughing, body mucus, wheezing, shortness of breath, chest pain and weight loss. Lung cancer has high mortality rate all over the globe and the foremost reason includes cigarette smoking. Treatments of lung cancer include chemotherapy and radiation therapy. This report provides in-depth discussion on global lung cancer therapeutics market and includes past and current trends with future forecast up to 2020. The report provides threats and opportunities for new and existing companies running the business in this market. The report is informative towards geographical segmentation and identifies profitable areas.
Global lung cancer therapeutics market shows promising CAGR due to increasing population of lung cancer and it is expected that trend would continue with the same momentum. Advanced stages of lung cancer still show high unmet need for diagnosis and treatment. The potential drivers for lung cancer therapeutic market include tobacco smoking (including passive smoke), aged population and lifestyle factors. Additionally, innovative and targeted drug delivery to lung is found to be a major driver for the growth of this market. However, high unmet need for diagnosis, availability of large number of generic forms of major drugs and limited treatment options are the critical restrains to the global lung cancer therapeutics market. Chemotherapy and radiation therapy poses bigger challenge of adverse effect. Hence, big players in this market have to focus on innovative therapies and safer therapeutics.
Global Lung Cancer Therapeutics Market by Therapeutics
The global lung cancer therapeutics market is segmented by therapy into five broad categories, namely Chemotherapy, Targeted therapy and Pipeline drugs, Surgery and Radiotherapy. NSCLC contributes for high prevalence than SCLC. Avastin by Roche was the blockbuster drug for the past few years that accounted for major percentage of the total sale. Other top brands of therapeutics include Gemzar, Taxotere and Tarceva and used for NSCLC. For SCLC treatment, ifosfamide or etoposide is combined with platinum analog and forms standard chemotherapeutic regimen. Many a times, Radiotherapy in combination with chemotherapy, is used as better option before surgery to increase the effectiveness of the treatment. Key Challenge in successful pipeline therapy includes its integration with existing therapy or its superiority over existing therapy.
Global Lung Cancer Therapeutics Market by Geography
Geographically, global lung cancer therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe are the leading global lung cancer therapeutic markets due to high incidences and large pool of aging population. Additionally, lifestyle standard with high smoking habits leads to a large pool of lung carcinoma population. Asia-Pacific is the emerging market, where India has shown high incidence in past few years, whereas, LAMEA contributes to smaller volume as compared to North America and Europe.
The leading companies in global lung cancer therapeutics market include Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Pfizer, and Agennix AG. Currently, Roche, Agennix AG and Pfizer are ruling the market for global lung cancer therapeutics and expected to capture half of the market share during the forecast period. Decline in sales value of AstraZeneca was attributed to large number of generic drugs entering the market. Eli Lilly has achieved a top position next to AstraZeneca and Sanofi-Aventis due to exceptional sales performance of its key product Alimta.
High Level Analysis
The study identifies the potential market drivers, challenges and trends. Competitive landscape section provides explicit information of the big players ruling the global lung cancer therapeutics market, their operating strategies, new launches, pipeline therapies and clinical trials. Porter’s five forces analysis has been used to determine the attractiveness of global lung cancer therapeutics market. Chemotherapy and radiation therapy shows large number of side effects and many a times need to be followed by surgery. Hence, constant demand for safe and efficacious therapeutics and improved technology is responsible to increase the bargaining power of suppliers. Large number of generic drugs is entering the market and therefore, the threat of substitute products tends to be high. To fulfill the demand for safe and effective drug therapy, many companies are putting their effort to pipeline research. Thus, it led to commercialization of large number of products and due to which rivalry is intense among participants.
This report offers the following benefits in particular:
Comprehensive coverage of global lung cancer therapeutics market along with disease overview, market trends, drivers and restraints
Through attention is given to leading company portfolios, pipeline research, new launches and competitive landscape of top players
Explicit information on current clinical trials and R&D activities, would be beneficial to understand the future market trends
Insightful analysis of different segments helps to recognize and capitalize future opportunities within global lung cancer therapeutics market
The global lung cancer therapeutics market is segmented into two major categories such as, therapeutics and geography.
Pneumectomy (Removal of whole lung)
Bilobectomy (Removal both lobes)
Lobectomy (removal of one lobe)
Let us know more about your research need and we will customize an offer exclusively for you!
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR)
encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only
engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates
and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within
each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors
and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis
and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and
allow stakeholders to make informed decisions.
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to:
Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
Flow cytometry is a biophysical, laser based analytical technology that measures and analyses several physical characteristics of cells or particles suspended in a fluid, when passed through a laser beam. Flow cytometry has various advantages over traditional analytical methods such as ELISA, which include its ability to deliver precise and accurate results and lesser time consumption at about same prices.
3D printing technology is a rapid emerging technology, which empowers manufacturers in the medical sector to produce customized medical equipment and products. 3D printing, also known as additive manufacturing, utilizes a layer-by-layer addition technique to produce physical objects from a three-dimensional digital file. The 3D printing technology caters to the rising demands of personalized medical care by providing customized medical devices based on individual needs.
Liver disease comprises of wide range of complex conditions affecting the liver. Liver disease treatment market is assured to grow on account of unmet clinical needs and upcoming treatment modifications. Number of novel agents has shown improvements in clinical trials such as obeticholic acid, thiazolidinediones and vitamin E for treatment of nonalcoholic fatty liver diseases. Additionally, according to American Cancer Society liver cancer rates increases 2.7% every year propelling the growth of liver disease treatment market.
The male infertility market is expected to grow to $301.5 million by 2020 with a CAGR of 4.9% during 2013-2020. Male infertility is defined as the inability of a male to impregnate his female partner after a year of unprotected intercourse. 20% of the total infertility is due to male factors. The major factors driving the male infertility market are the change in lifestyle, increasing age, environmental effects, etc., and these factors are majorly contributing to the rise in male infertility levels. The major limitation experienced in the male infertility market is due to repeated treatment failures leading to an emotional impact on the patient.
The global melanoma market has witnessed an unprecedented boost in market size, owing to a dynamically evolving nature of melanoma treatments over the past few years. The high demand of novel early stage and advanced melanoma therapies along with a booming patient base, has created an impending need for better therapies in the melanoma market. Although, a plethora of treatment options are available today, several immunotherapies and combination therapies ar
Osteoporosis is a condition in which the bones become weak and fragile due to the loss of tissue. This condition can arise due to hormonal changes, the deficiency of calcium or vitamin. In osteoporosis, the microstructure of bones is changed due to the change in bone mass and bone density. Osteoporosis can cause severe injury or pain and requires timely treatment.
Breast imaging is a technique which is used to obtained high resolution visualization of breast and breast related diseases. Breast cancer is the most common cancer found in women. Breast imaging techniques play a major role in early diagnosis of the disease, evaluating the progress of the disease and deciding which treatment is suitable. This imaging technique enables doctors to monitor the efficacy of treatment and how patients would respond to it.